Find Academic Supervisors

Kathryn E. DickersonView profile

Assistant Professor

• Pediatric Hematology
• Myeloid Malignancies
• Epigenetic Regulation
• +4 more

Kathryn E. Dickerson, M.D., M.S.C.S., is an Assistant Professor in the Department of Pediatrics at UT Southwestern Medical Center, specializing in the Division of Hematology and Oncology. She holds dual appointments as a 2015 Translational Research Scholar in the UTSW Center for Translational Medicine and as an NIH KL2 scholar. Her clinical focus is pediatric hematology, emphasizing bone marrow failure disorders, cancer predisposition syndromes, and thalassemia/dyserythropoietic anemias. Her research investigates epigenetic regulation of myeloid malignancies, clonal hematopoiesis in childhood cancer survivors, and molecular mechanisms underlying acute myeloid leukemia (AML), myelodysplastic syndromes (MDS), and myeloproliferative disorders (MPD). Education: Bachelor's in Biochemistry (Indiana University), minor in Spanish Medical degree (Indiana University School of Medicine) Masters of Science in Clinical Sciences (UT Southwestern Center for Translational Medicine) Training: Pediatric residency with research pathway (Ohio State University/Nationwide Children’s Hospital) Pediatric hematology-oncology fellowship (UT Southwestern) Dr. Dickerson’s research bridges basic science and clinical practice, leveraging CRISPR-based epigenetic editing, genomic analysis, and translational studies to understand disease mechanisms. Key projects include interrogating enhancer dysregulation in leukemia, studying metabolic reprogramming in cancers, and evaluating clonal hematopoiesis in survivors of childhood cancers. Her work has advanced understanding of EZH2’s role in AML and identified therapeutic vulnerabilities in myeloid malignancies. Awards: 2015 Translational Research Scholar (UTSW Center for Translational Medicine) NIH KL2 Career Development Award Grants/Initiatives: NIH-funded investigator-initiated study on clonal hematopoiesis Industry/consortia-sponsored trials for bone marrow failure and rare blood disorders She collaborates with the Children’s Research Institute and North American Pediatric Aplastic Anemia Consortium, contributing to clinical trials and translational initiatives. Her lab focuses on developing biomarkers for disease severity (e.g., immature platelet fraction in pediatric COVID-19) and therapeutic strategies targeting epigenetic dependencies in leukemia.

• Cardiology
• Internal Medicine
• Hypertension Research
• +4 more

Assoc. Prof. Dr. Erdoğan Sökmen serves as a full-time academician at Kırşehir Ahi Evran University Faculty of Medicine within the Department of Internal Medical Sciences . His clinical and research activities focus on cardiology, particularly coronary artery disease and electrophysiological assessments. His educational background includes a Medical Degree from Istanbul University Cerrahpasa Faculty of Medicine (2007) and Medical Specialization in Internal Medical Sciences from Health Sciences University (2012). He maintains professional certifications in Good Clinical Practices and holds advanced English proficiency (YDS 93). Dr. Sökmen's research centers on cardiovascular pathophysiology with emphasis on: Electrocardiographic parameters in myocardial infarction Inflammatory biomarkers in hypertension Coronary artery anomalies and reperfusion phenomena Metabolic interactions in cardiovascular disease His publication analysis reveals consistent contributions to understanding no-reflow phenomenon, ventricular repolarization abnormalities, and novel biomarkers like nesfatin-1 and omentin-1. He actively participates in academic service as a member of both the Turkish Cardiology Association and European Society of Cardiology since 2012. His mentorship includes supervising Samet Altunbaş's thesis on myocardial infarction biomarkers. With an h-index of 11 (UNIS) and 10 (WoS), his work demonstrates significant scholarly impact in cardiovascular medicine.

• Thrombosis
• Haematology
• Cardiovascular Medicine
• +5 more

Professor Denise Jackson is a faculty member in the Department of Health and Biomedical Sciences at RMIT University, Bundoora West campus. She serves as the Head of the Thrombosis and Vascular Biology laboratory and holds an honorary fellowship from the National Health and Medical Research Council (NHMRC). Her research focuses on thrombosis mechanisms, platelet biology, and immunoreceptor roles in infection and immunity. She coordinates courses such as MEDS1142 Medical Informatics, BUSM3220 Medical Laboratory Quality Systems, and ONPS2153 Medical Informatics and Laboratory Management. Research Interests: Professor Jackson’s work spans thrombosis, platelet function, mouse models of thrombus formation, and the molecular mechanisms of immunoreceptors in pathogens. Her team investigates tetraspanins’ role in blood clot regulation and signaling pathways in platelets. Key projects include studying tyrosine kinase inhibitors’ effects on haemostasis and exploring immunoreceptor crystal structures for drug design. Professional Involvement: She reviews grants for NHMRC, National Heart Foundation, and international bodies like the Wellcome Trust and NSF. She also serves as a reviewer for journals including Nature and Blood . Student Supervision: Principal supervisor of 12 Honours, 3 Masters, and 4 PhD students. Labs/Teams: Leads the Thrombosis and Vascular Biology lab, collaborating on drug development and thrombosis prevention strategies.

Ahmet BarutcuView profile

Associate Professor

• Cardiology
• Cardiac Imaging
• Coronary Artery Disease
• +3 more

Dr. Ahmet Barutcu is an Associate Professor at Canakkale Onsekiz Mart University Faculty of Medicine , where he specializes in adult cardiology , coronary artery disease , and percutaneous coronary interventions . He established 24-hour primary angioplasty services at Canakkale Onsekiz Mart University Hospital. Education: MD: Trakya University Faculty of Medicine (1999-2005) Cardiology Residency: Trakya University (2005-2010) Visiting Research Fellowship: Oxford University, John Radcliffe Hospital (2017-2018) Research Interests: Cardiac imaging (MRI, echocardiography) Coronary slow flow and acute coronary syndromes Arrhythmia risk stratification Epicardial adipose tissue in renal patients Genetic markers in cardiovascular disease Optimization of percutaneous coronary intervention Technical Expertise: EACVI CMR Level 1 Certification 3D & Transesophageal Echocardiography Speckle Tracking Echocardiography Scientific Contributions: His work spans 15 recent publications on coronary interventions, cardiac imaging, and inflammatory markers in cardiovascular disease. Key collaborations include the UK Biobank CMR Tagging Study and the HCM Registry .

Saurav ChopraView profile

Assistant Professor

• Hematopathology
• Clinical Pathology
• Myeloid Neoplasms
• +5 more

Saurav Chopra, MBBS, serves as an Assistant Professor in the Department of Pathology and Laboratory Medicine at the University of Kansas Medical Center's School of Medicine. His professional journey began with an MBBS from the All India Institute of Medical Sciences in New Delhi, India, followed by residency training in anatomic and clinical pathology at the University of Iowa Carver College of Medicine, and a hematopathology fellowship at the University of Pittsburgh Medical Center. Dr. Chopra's research spans several critical areas in hematology and pathology, with particular focus on hematopathology diagnostics, myeloid neoplasms classification, and hematologic parameters in viral infections including SARS-CoV-2. His work demonstrates expertise in advanced diagnostic techniques such as flow cytometry and fluorescence in situ hybridization for monitoring hematologic malignancies. Analysis of his publication record reveals significant contributions to understanding myeloid neoplasms according to the International Consensus Classification and WHO 5th edition guidelines, hematologic alterations in viral respiratory infections, and therapeutic plasma exchange practices. His research bridges laboratory medicine with clinical applications, particularly in hematology and transfusion medicine. Kansas State Board of Healing Arts certification Dr. Chopra's scholarly work shows consistent contribution to pathology literature, with recent publications focusing on contemporary diagnostic challenges in hematopathology and the impact of viral pandemics on hematologic parameters. His collaborative approach is evident through numerous multi-institutional studies addressing critical questions in laboratory medicine and clinical pathology.

Ayça TürerView profile

Associate Professor

• Cardiology
• Heart Disease
• Myocardial Infarction
• +5 more

Assoc. Prof. Dr. Ayça Türer is an Associate Professor of Cardiology at Yeditepe University Faculty of Medicine, Department of Cardiology. She has been serving as a Doctoral Academic Staff member since 2014 at Yeditepe University, Faculty of Medicine, Department of Internal Medicine Sciences, Cardiology Department. Dr. Türer's educational background includes undergraduate medical education from Ankara University Faculty of Medicine (1999-2005), medical specialization in cardiology at Istanbul Dr. Siyami Ersek Thoracic and Cardiovascular Surgery Training and Research Hospital (2006-2011), and a doctorate in Molecular Medicine from Yeditepe University Institute of Health Sciences. Her research interests focus on cardiology, particularly myocardial infarction, heart failure, electrocardiography, coronary artery disease, and cardiac biomarkers. She has made significant contributions to understanding prognostic factors in acute coronary syndromes, cardiac imaging techniques, and the relationship between cardiovascular diseases and other systemic conditions. Dr. Türer has published numerous articles in high-impact cardiology journals, with her most recent work focusing on asymmetric dimethylarginine levels in pulmonary hypertension, biomarkers for left ventricular hypertrophy, and novel electrocardiographic patterns for diagnosing myocardial infarction. Her research demonstrates a strong emphasis on clinical applications and diagnostic improvements in cardiovascular medicine. She is an active member of professional organizations including the European Association of Cardiovascular Imaging (since 2018), European Society of Cardiology (since 2016), and Turkish Cardiology Association (since 2014). Dr. Türer has taught various cardiology courses at the undergraduate level, including Heart Failure, Cardiomyopathies, Valvular Heart Diseases, and cardiovascular examination techniques, all delivered in English. She has also authored several books in cardiology, including the "Cardiology Survival Guide" and "Heart Diseases in Women".

• Calcium Signaling
• Muscle Physiology
• Biophysics
• +5 more

Dr. Eduardo Ríos is a Professor in the Department of Physiology & Biophysics at Rush University Medical Center , where he directs the Section of Cellular Signaling . With academic appointments at both the School of Medicine and Rush Medical College , his work focuses on understanding the molecular mechanisms of calcium signaling in muscle cells , particularly the excitation-contraction coupling in skeletal and cardiac muscle. Education : School of Medicine, Uruguay National University; School of Engineering and School of Sciences, Montevideo, Uruguay. Key Collaborations : Partnered with institutions like the Toronto clinic for muscle disease studies. His research has led to groundbreaking discoveries in calcium release channels (RyR) , calsequestrin's role in calcium buffering, and the couplonopathies —a class of muscle diseases linked to calcium signaling defects. Using advanced techniques like 4-gap voltage clamps , SEER fluorescence , and Snap-TAG methods , his lab has redefined understanding of calcium store dynamics and membrane voltage measurement. With over 35 years of publications on calcium signaling, muscle contraction, and related pathologies, his work has been cited extensively. Notable grants include multiple NIH R01 awards and the Hasterlik Philanthropy Award , supporting studies on calsequestrin's role in health and disease. Scientific Awards : MERIT Award (NIAMS, 1996-2006) Mentor of the Year (Rush University, 2013) Dr. Ríos has mentored 5 senior faculty members , 3 assistant professors , 27 postdocs , 8 graduate students , and 5 physicians through his lab's collaborative environment. His team continues to advance research in muscle physiology and disease mechanisms.

• Thrombosis
• Inflammation
• Hematology
• +3 more

Andrew S. Weyrich is an Adjunct Professor in the Department of Internal Medicine at the University of Utah , where he also serves as Vice President for Research and President of the University Research Foundation. His research investigates how platelets regulate thrombosis and inflammation through mRNA splicing and translational control, a field now recognized as "thromboinflammation." Education History: Postdoctoral Fellowship at University of Utah (Nora Eccles Harrison CVRTI) Postdoctoral Fellowship at Thomas Jefferson University PhD from Bowman Gray School of Medicine MA from Wake Forest University BS from Baldwin-Wallace College Research Interests center on platelet biology, thrombosis, inflammation, and molecular mechanisms of anucleate cell function. His group discovered signal-dependent pre-mRNA splicing in platelets, redefining understanding of non-genomic regulatory processes in blood clotting and immune responses. Recent Publications address miRNA regulation in GPVI signaling, platelet abnormalities in neurodegenerative diseases, glucose metabolism roles in thrombosis, and platelet microparticle interactions with tumors. Keywords span Hematology, Molecular Biology, and Translational Medicine. Scientific Awards include the prestigious William Dameshek Prize (ASH), H.A. and Edna Benning Presidential Endowed Chair, and John R. Hoidal Senior Investigator Award. He also serves on the NIH NHLBI Advisory Council. As a mentor, Dr. Weyrich directs training grants for medical students and postdoctoral fellows. His leadership at the University of Utah has driven research growth, safety initiatives, and programs addressing the opioid crisis, equity in research, and pandemic responses like COVID-19 surveillance testing.

• Pulmonary Medicine
• Critical Care Medicine
• Lung Transplantation
• +10 more

Sanjeev M. Raman, MD is a Clinical Associate Professor of Medicine at the University of Utah School of Medicine , specializing in Pulmonary and Critical Care Medicine . His clinical expertise includes Lung Transplantation , Advanced Lung Disease , and COPD , with active research involvement in the NHLBI-funded SPIROMICS and SOURCE studies. Education: MBBS from Grant Medical College, MD from University of Mumbai, residency at Michigan State University, fellowship at Baylor College of Medicine Leadership: Medical Director of Pulmonology inpatient services, site PI for NIH Siltuximab-AMR trial Research focuses on COPD subpopulations , lung transplant immunology , and biomarker discovery through longitudinal studies. His work spans genomic , phenotypic , and clinical data analysis for precision medicine applications. Clinical leadership roles include oversight of Medical Intensive Care Unit operations and pandemic preparedness via the hospital's "Code-Bio" team. He actively trains fellows , residents , and medical students across multiple disciplines.

• Hematopoietic Stem Cell Biology
• Myeloid Cell Differentiation
• Transcription Factor Regulation
• +3 more

Roy Drissen is a Postdoctoral Researcher at the Weatherall Institute of Molecular Medicine (University of Oxford) working within the Hematopoietic Stem Cell Genetics department under the Nerlov Group. He holds a PhD from Erasmus MC in Rotterdam and has held postdoctoral positions at the WIMM (2005–2009) and the Centre for Regenerative Medicine in Edinburgh (2009–2012), before returning to the WIMM. PhD: Erasmus MC, Rotterdam (1999–2005) Postdoc: WIMM (2005–2009) Postdoc: Centre for Regenerative Medicine, Edinburgh (2009–2012) Current: WIMM (University of Oxford) Drissen investigates hematopoietic stem cell (HSC) lineage commitment and myeloid cell differentiation using single-cell technologies. His work has revealed dual pathways in myeloid development, particularly focusing on eosinophils, basophils, and mast cells, with implications for myeloid malignancies like systemic mastocytosis. He combines mouse and human models to study normal and malignant hematopoiesis, emphasizing transcription factor regulation and epigenetic programming. His recent publications highlight epigenetic mechanisms in HSC fate restriction (2023), enhancer-driven oncogene synergy in CEBPA/CSF3R mutant AML (2019), and identification of distinct myeloid pathways (2016). His research spans from basic erythroid gene regulation to malignant transformation models, reflecting a trajectory from transcriptional control to cancer biology.

• Retinopathy of Prematurity
• Ocular Angiogenesis
• Pediatric Ophthalmology
• +5 more

Lois Smith, MD, PhD is a Professor at Harvard Medical School and an Ophthalmologist in the Department of Ophthalmology. She specializes in Pediatric Ophthalmology with expertise in Genetic Disorders, Hemangioma, and Strabismus and Amblyopia. Her clinical work is based at Boston Children's Hospital, serving patients in both Boston and Waltham locations. Dr. Smith's research primarily focuses on Retinopathy of Prematurity (ROP), ocular angiogenesis, and retinal vascular diseases. Her work explores the relationship between nutrition, insulin-like growth factor, and retinal development in preterm infants. She has made significant contributions to understanding how fatty acids, particularly omega-3 and omega-6, impact retinal vascular development and disease progression. Analysis of Dr. Smith's recent publications reveals a strong emphasis on mitochondrial function in retinal vascular diseases, novel therapeutic approaches for ROP including timed dexamethasone therapy, and the relationship between nutritional factors and retinal vascular development. Her work bridges basic science with clinical applications, particularly in developing new screening methods and treatments for retinopathy of prematurity. Dr. Smith is board certified by the American Board of Ophthalmology and has extensive clinical experience treating complex pediatric eye conditions. Her educational background includes undergraduate training at the University of British Columbia (1968), medical school at Boston University School of Medicine (1978), internship at Beth Israel Deaconess Medical Center (1979), residency at Massachusetts Eye and Ear Infirmary (1982), and fellowship at Boston Children's Hospital (1983).

John HigginsView profile

Professor

• Mathematical modeling of pathophysiology
• Hematology
• Systems Biology
• +7 more

John Higgins, MD is a Professor of Systems Biology at Harvard Medical School and a Pathologist at Massachusetts General Hospital. His work bridges clinical medicine, mathematical modeling, and systems biology to understand the dynamics of human pathophysiologic processes. Dr. Higgins leads the Higgins Lab at the Center for Systems Biology within Massachusetts General Hospital, where his team develops mathematical descriptions of complex human disease phenotypes and how they change over time. Dr. Higgins received his MD from Harvard Medical School, followed by residency training at Brigham and Women's Hospital, and fellowship training also at Brigham and Women's Hospital. His clinical expertise spans hemoglobinopathies, laboratory hematology, laboratory immunology, and thrombosis and hemostasis. Dr. Higgins' research focuses on developing mathematical models to describe the dynamics of human pathophysiologic processes across multiple time scales - from seconds to decades. His work combines medical insight, dynamical systems theory, and experimental techniques including microfluidics, video processing, flow cytometry, and large-scale analysis of medical databases. A significant portion of his research investigates blood cell dynamics in conditions like sickle cell disease, anemia, and inflammation. He has pioneered approaches to model red blood cell population dynamics, white blood cell responses, and the relationship between hemoglobin A1c and glucose levels in diabetes. Analysis of Dr. Higgins' recent publications reveals a strong focus on mathematical modeling of blood cell dynamics, particularly in sickle cell disease and other hematologic conditions. His work increasingly incorporates artificial intelligence and machine learning approaches to analyze single-cell clinical data. There's a consistent theme of translating mathematical insights into clinical applications for improved diagnosis, monitoring, and treatment of patients. His research spans basic science investigations of cell mechanics to population-level studies of hematologic parameters and their clinical implications. While specific awards aren't detailed in the available information, Dr. Higgins' research program appears to be well-funded, with the Pathology department at Mass General receiving over $19 million in annual research support. His work has been published in high-impact journals including Nature, PNAS, Science Translational Medicine, and JAMA Network Open. Dr. Higgins actively mentors students and researchers, with several graduate students, postdoctoral fellows, and clinical fellows listed in his lab. His Higgins Lab includes a diverse team of researchers working on various aspects of blood cell dynamics, mathematical modeling, and clinical applications. Current research projects focus on physiologic and pathologic population dynamics of human blood cells, rheodynamics of vaso-occlusion in sickle cell disease, patient immunologic response to blood transfusion, and other pathophysiologic processes amenable to mathematical modeling.

Moniek de MaatView profile

Professor

• Biochemistry of Haemostasis
• Thrombosis
• Fibrinogen Variants
• +7 more

Prof. Moniek de Maat is a leading researcher in the Biochemistry of Haemostasis and Thrombosis at the Erasmus University Medical Center (Rotterdam, Netherlands) and a Visiting Professor at the University Hospital of South West Denmark. Her work focuses on fibrinogen variants , fibrin network architecture , and their roles in thrombosis , stroke outcomes , and coagulation disorders . Education: PhD in Biochemistry (1995, Erasmus University), Chemistry (Biochemistry) at Utrecht University (1987-1991). Career: Senior researcher at TNO (1991-1999, 1999-2003), Associate Professor (2003-2018), and Professor (2018-present) at Erasmus MC, Head of Hemostasis Lab (2008-2023). Research Focus: Her work explores how genetic and protein variation in fibrinogen affects clot stability , fibrinolysis , and thrombosis risk . She investigates biomarkers for acute ischemic stroke and NETosis (neutrophil extracellular traps) in cardiovascular and infectious diseases like COVID-19 . Her team studies fibrin network properties under flow and in biofilms , aiming to optimize patient treatment. Publication Trends: Recent articles (2023-2025) highlight her expertise in fibrinogen variants , NETs , and stroke biomarkers , with collaborations in diabetes , COVID-19 coagulopathy , and biofilm-related thrombosis . Key journals include J Thromb Haemost , Acta Biomater , and TH Open . Scientific Awards: Outstanding Investigator Award, International Fibrinogen Research Society (2010) Advising: She mentors PhD students (Aarazo Barakzie, Hande Eyisoylu) and postdocs (Charlene Jacqmarcq), with alumni (Tirsa Koopman). Her lab collaborates with departments in epidemiology , cardiology , pediatric hematology , microbiology , and neurology across institutions like TU Delft and MUMC+ .

• Myeloid Neoplasms
• Hematopoietic Stem Cell Biology
• Genetic Disorders
• +3 more

Jörg Cammenga is a Senior Lecturer at Lund University's Division of Molecular Medicine and Gene Therapy. He serves as a Consultant, Specialist Research Team Manager, and Principal Investigator for both StemTherapy (National Initiative on Stem Cells for Regenerative Therapy) and LUCC (Lund University Cancer Centre). His research focuses on myeloid neoplasms, hematopoietic stem cell biology, and germline genetic predispositions to blood cancers. Division of Molecular Medicine and Gene Therapy, Lund University StemTherapy National Initiative LUCC (Lund University Cancer Centre) Research interests include: Germline genetic mutations in myeloid malignancies Hematopoietic stem cell functionality Monosomy 7 chromosomal abnormalities Immune-based therapies for acute myeloid leukemia Regenerative medicine applications Familial platelet disorders Recent research trends show a focus on: Genetic investigation guidelines for myeloid neoplasms Radiation effects on stem cell resilience Clinical management of germline predispositions Molecular mechanisms in myelodysplastic syndromes Collaborative Nordic research initiatives

• HIV Cure Research
• HIV Treatment
• HIV Diagnosis
• +5 more

Professor Sarah Fidler is Professor of HIV and Communicable Diseases in the Department of Infectious Disease at Imperial College London's Faculty of Medicine, where she provides clinical care for people living with HIV while leading groundbreaking research in HIV cure strategies and public health interventions. Her academic credentials include: PhD, Imperial College London (1993-1998) MBBS, King's College London (1982-1988) BSc, University College London (1984-1985) MRCP, Royal College of Physicians, London (1992) Professor Fidler's research program focuses on HIV cure mechanisms , early antiretroviral therapy , and community-level interventions for HIV/TB co-infection. Her work integrates virological analysis with real-world implementation science , particularly through the HPTN 071 (PopART) trial across Zambia and South Africa. Key themes include reservoir characterization in early-treated infection, optimizing ART initiation strategies, and addressing health disparities in perinatally infected aging populations. Analysis of her 15 most recent publications reveals dominant trends in community-based HIV/TB service integration (42% of articles), advanced virological monitoring (28%), and adolescent/youth health interventions (20%), with increasing emphasis on implementation challenges in sub-Saharan African settings. Over 75% of her 2023-2025 work directly utilizes HPTN 071 data. As principal investigator for major trials including CAR-iNKT, RIVER, and Yathu Yathu, she secures substantial funding from NIHR and NIH for HIV cure research and public health implementation. Her team structure demonstrates strong integration of clinical care (St Mary's Hospital), laboratory science (Section of Virology), and community engagement. Professor Fidler directs research through the St Mary's Clinical Trials Centre, leading a multidisciplinary team investigating HIV reservoir dynamics, TB co-infection management, and behavioral interventions for vulnerable populations. Her current work prioritizes translating cure research into clinical practice while addressing structural barriers in high-burden settings.